168 related articles for article (PubMed ID: 1655244)
1. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
3. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
4. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
5. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
7. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
8. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
9. Relationship of VP-16 to the classical multidrug resistance phenotype.
Sehested M; Friche E; Jensen PB; Demant EJ
Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
[TBL] [Abstract][Full Text] [Related]
10. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
11. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
12. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
13. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
14. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
15. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.
Petersen LN; Jensen PB; Sørensen BS; Engelholm SA; Spang-Thomsen M
Invest New Drugs; 1994; 12(4):289-97. PubMed ID: 7775129
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
17. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
18. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
19. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
Bridewell DJ; Finlay GJ; Baguley BC
Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]